Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9573 posts found.

GSK-Genmab blood cancer drug approved in US

November 2, 2009 Research and Development, Sales and Marketing Arzerra

GlaxoSmithKline and Philadelphia-based Genmab have received accelerated US approval for their blood cancer drug Arzerra. It is to be used …
News

AstraZeneca withdraws filings for lung cancer drug

November 2, 2009 Research and Development, Sales and Marketing AZ, zactima

AstraZeneca has withdrawn marketing applications for its lung cancer drug Zactima in Europe and the US after evaluating updated results …
News

GSK begins phase III COPD trials

October 28, 2009 Research and Development, Sales and Marketing COPD, GSK, GlaxoSmithKline, Seretide, Theravance, resp, respiratory

GlaxoSmithKline and San Francisco biopharma firm Theravance have begun a phase III trial to develop a new treatment for chronic …
News
Tarceva tablets

Comparing notes: UK’s cancer leaders discuss the latest advances

October 28, 2009 Research and Development, Sales and Marketing Cancer

 
Feature
Ipsen Claude

Claude Bertrand joins Ipsen as Chief Scientific Officer

October 27, 2009 Research and Development appointment, ipsen, research and development

Ipsen has appointed Claude Bertrand (pictured) chief scientific officer and Jacques-Pierre Moreau chief scientific advisor.Bertrand moves to the company next …
Appointment

Quintiles will open new clinical unit in London next year

October 27, 2009 Research and Development NHS, Quintiles

Quintiles has agreed to set up a clinical research unit in London that will allow it to tap into the …
News

Consolidation wave likely to continue among European CROs

October 27, 2009 Research and Development cros

Another report concluding that the most successful contract research organisations (CROs) will be those that can offer a broad range …
News

Contract research news in brief

October 26, 2009 Research and Development cros

Pharmafocus' round-up of contract research news includes ICON's Q3 results, expansion plans at ClinTec and a prestigious award for Bilcare
News

Critical Pharma gets Wellcome funding for biologic spray technology

October 26, 2009 Research and Development critical pharma

A nasal spray technology which promises an alternative drug delivery method for biologic drugs has been given a funding boost. …
News

Andrew Sandham, executive chairman, Syntaxin

October 20, 2009 Research and Development appointment, appointments, research and development, syntaxin

Syntaxin, a biopharmaceutical company developing novel biologic drugs that control cell secretion, has appointed Andrew Sandham executive chairman.This follows the …
Appointment
Cellectis Sylvie

Cellectis appoints Dr Sylvie Delassus Senior Vice President Communications

October 20, 2009 Research and Development appointment, cellectis, research and development

French genome engineering company Cellectis has appointed Dr Sylvie Delassus senior vice president communications and a member of its executive …
Appointment
Blog footer

Digital Pharma: Raising awareness of clinical trials

October 20, 2009 Medical Communications, Research and Development CRO, Quintiles, digi, digital pharma, digital research, patient recruitment

Contract research organisation Quintiles has launched a website for people considering participating in clinical trials. The company hopes Clinicalresearch.com will …
Feature

GSK kidney cancer drug approved in US

October 20, 2009 Research and Development, Sales and Marketing Cancer, GSK, rcc

 GlaxoSmithKline’s Votrient has been approved in the US by the FDA to treat the most common form of kidney cancer.This …
News

First details emerge of Pfizer site closures

October 20, 2009 Research and Development, Sales and Marketing MA, Pfizer, restructure

 The completion of Pfizer’s deal to acquire Wyeth has been followed swiftly by news that a number of manufacturing and …
News

Cambridge biotech – innovation and global partnerships

October 19, 2009 Research and Development Cambridge, ERBI, biotech, regenerative medicine

Just two years ago it cost $10m to sequence a human genome, now for $48,000 you can have a personal …
Feature
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025